Clinical Medicine Reviews in Therapeutics

Golimumab-A Review of its Therapeutic Efficacy in Rheumatoid Arthritis

Submit a Paper

Clinical Medicine Reviews in Therapeutics 2010:2


Published on 12 Jul 2010

DOI: 10.4137/CMRT.S4775

Further metadata provided in PDF

Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Therapeutics


The advent of monoclonal antibodies to Tumor necrosis factor-α (TNF), has revolutionized the treatment in rheumatoid arthritis (RA). These agents have proved to be highly efficacious, making remission an achievable goal in RA. Golimumab is a human monoclonal antibody to TNF, which is approved by the US FDA for the treatment of RA, psoriatic arthritis and ankylosing spondylitis since April 2009. Golimumab is a useful addition to the therapeutic armamentarium against rheumatoid arthritis. It has proven efficacy in RA patients with active disease, despite treatment with methotrexate and also found to be useful in patients who have failed on a prior anti-TNF agent. It offers a reasonable alternative to other anti-TNF drugs like infliximab, adalimumab or etanercept. The short-term safety profile, based on short-term RCTs, is reasonable with no differences in total adverse events, serious infections, cancer, tuberculosis or deaths. However, Long-term surveillance studies are needed for safety assessment.



BibTex citation   (BIBDESK, LATEX)

What Your Colleagues Say About Libertas Academica
Libertas Academica really cares about authors of submitted papers.  Its policy guarantees that every submitted paper will receive responsible and professional review comments.
Dr Hao Yu (Johns Hopkins University, Baltimore, USA)
More Testimonials

Quick Links

New article and journal news notification services